Study uncovers possible genetic markers in breast cancer that spreads to the brain

February 10, 2014, The Translational Genomics Research Institute

The Translational Genomics Research Institute (TGen) has uncovered possible genetic origins of breast cancer that spreads to the brain, according to a first-of-its-kind study published in the scientific journal PLOS ONE.

The compendium of genetic targets uncovered by TGen now can be used to identify potential new methods of diagnosis and new drug therapies for the estimated 45,000 patients in the U.S. each year whose cancer spreads from the breast to the brain.

The 3-year study is significant since these patients currently have few treatments options—surgery and radiation—and they usually are ineligible for clinical drug trials. Their prognosis is poor, with fewer than 2 percent surviving more than two years

"This is really a significant problem and a huge unmet need. We now want to dig deeper and uncover more specific genomic links and study new ways to treat these patients so we can improve outcomes," said Dr. Bodour Salhia, an Assistant Professor in TGen's Integrated Cancer Genomics Division and the study's lead and co-senior author.

"In this study, we see that breast-brain metastasis retain many features found in primary breast cancer, but we still need to better understand the differences," said Dr. Salhia. "Knowing the key drivers of brain metastasis may lead to preventive measures, as well."

After lung cancer, breast cancer is the second most common cancer that spreads to the brain. Chemotherapy generally has not been used to treat brain cancer, because of the blood-brain barrier that exists between the bloodstream and the cerebrospinal fluid surrounding the brain. However, some small molecule drugs can cross this barrier and form the basis of targeted therapies.

The overall goal of the TGen study was to look at genomic and epigenomic events to understand the causes of brain metastatic lesions, and identify potential new therapeutic targets.

The TGen team performed deep genomic profiling, integrating gene copy number, gene expression and DNA methylation datasets on a collection of 35 breast- metastases samples. The study, Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain Metastasis, published Jan. 29, is the first of its kind to incorporate all of those avenues of inquiry in the study of this disease.

Some of the common genetic alterations identified in the study were gains and losses in chromosome 8, as well as cell proliferation and cell-cycle progression—key mechanisms of cancer caused by genetic alterations—linked to the genes AURKA, AURKB and FOXM1.

"This groundbreaking study sets the stage for more exacting research, using the latest genomic technologies and aimed at developing new therapies that could help the tens of thousand of patients who urgently need our help," said Dr. Nhan Tran, an Associate Professor of TGen's Cancer and Cell Biology Division and the study's other co-senior author.

Explore further: Scientists link protein with breast cancer's spread to the brain

Related Stories

Scientists link protein with breast cancer's spread to the brain

January 6, 2014
A cancer-research team at the University of Wisconsin-Madison has identified a protein that may be a major culprit when breast cancer metastasizes to the brain.

Breast cancer cells disguise themselves as neurons to cause brain tumors

January 15, 2014
Treatment and "cure" of breast cancer doesn't ensure that the disease won't spread to the brain. Too often, sometimes years after an initial diagnosis and remission, breast cancer cells are discovered growing as new tumors ...

First large-scale study of whole-genome testing helps identify best treatment for women with advanced breast cancer

February 6, 2014
The first large-scale study testing all the DNA—the entire genome—of tumor cells from more than 400 women with advanced breast cancer has identified individuals with a good chance of benefiting from specific treatments ...

Breast cancer prognosis associated with oncometabolite accumulation

December 9, 2013
The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. In this issue of the Journal of Clinical Investigation Stefan Ambs and colleagues at the National ...

Study shows TWEAK-Fn14 is drug target for cancer

November 8, 2013
(Medical Xpress)—A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, ...

MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients

February 5, 2013
Researchers have identified two molecules that could potentially serve as biomarkers in predicting brain metastases in patients with breast cancer, according to data published in Cancer Research, a publication of the American ...

Recommended for you

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.